A Study of IGN002 for Refractory NHL

Withdrawn before enrolling · Phase 1

Conditions studied: NHL

In brief

This is a Phase 1 multi-center, open-label study that allows subjects who derived clinical benefit after completing IGN002 treatment in the Spectrum sponsored IGN002-101 study to continue treatment with IGN002. Subjects who completed the IGN002-101 study, tolerated IGN002 treatment, and did not experience progressive disease (PD) are eligible to participate in this study.

Key facts

Study ID
NCT02847949
Run by
Spectrum Pharmaceuticals, Inc
People needed
0
Starts
2021-01-01
Expected to finish
2025-12-01
Last updated by the study team
2022-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.